It has been demonstrated that niclosamide can suppress tumor growth in different cancer types, e.g., adrenocortical carcinoma (Khan et al., 2016), glioma (Wieland et al., 2013), and leukemia (Chae et al., 2018), as well as head and neck (Wang et al., 2017), breast (Yin et al., 2016), lung (Xiang et al., 2017), ovarian (Arend et al., 2016), prostate (Lu et al., 2011) and renal (Yu et al., 2018) cancers via different mechanisms, including inhibition of Wnt, Notch, mTOR, and NF-κB signaling. This evidence concerns the gene NFKB1 and cancer.